Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has gone decline by -2.91 in comparison to its previous close of 82.00, however, the company has experienced a 14.46% increase in its stock price over the last five trading days. The Motley Fool reported 2024-03-31 that Viking Therapeutics may be on the verge of a breakthrough obesity care treatment. Right now, obesity care and diabetes are dominated by Novo Nordisk and Eli Lilly.
Is It Worth Investing in Viking Therapeutics Inc (NASDAQ: VKTX) Right Now?
Moreover, the 36-month beta value for VKTX is 1.05. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VKTX is 99.62M and currently, short sellers hold a 11.18% of that float. On April 01, 2024, VKTX’s average trading volume was 6.51M shares.
VKTX’s Market Performance
VKTX stock saw an increase of 14.46% in the past week, with a monthly gain of 3.32% and a quarterly increase of 313.13%. The volatility ratio for the week is 8.28%, and the volatility levels for the last 30 days are 10.49% for Viking Therapeutics Inc (VKTX). The simple moving average for the last 20 days is 7.10% for VKTX’s stock, with a simple moving average of 239.20% for the last 200 days.
Analysts’ Opinion of VKTX
Many brokerage firms have already submitted their reports for VKTX stocks, with Oppenheimer repeating the rating for VKTX by listing it as a “Outperform.” The predicted price for VKTX in the upcoming period, according to Oppenheimer is $138 based on the research report published on March 26, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $110. The rating they have provided for VKTX stocks is “Buy” according to the report published on March 07th, 2024.
Oppenheimer gave a rating of “Outperform” to VKTX, setting the target price at $116 in the report published on February 28th of the current year.
VKTX Trading at 59.61% from the 50-Day Moving Average
After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.92% of loss for the given period.
Volatility was left at 10.49%, however, over the last 30 days, the volatility rate increased by 8.28%, as shares sank -7.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +276.17% upper at present.
During the last 5 trading sessions, VKTX rose by +13.26%, which changed the moving average for the period of 200-days by +240.11% in comparison to the 20-day moving average, which settled at $74.01. In addition, Viking Therapeutics Inc saw 327.78% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VKTX starting from Lian Brian, who sale 45,000 shares at the price of $29.90 back on Feb 09 ’24. After this action, Lian Brian now owns 2,139,882 shares of Viking Therapeutics Inc, valued at $1,345,500 using the latest closing price.
Lian Brian, the President & CEO of Viking Therapeutics Inc, sale 269,079 shares at $26.87 during a trade that took place back on Feb 08 ’24, which means that Lian Brian is holding 2,184,882 shares at $7,230,784 based on the most recent closing price.
Stock Fundamentals for VKTX
The total capital return value is set at -0.29. Equity return is now at value -34.79, with -31.99 for asset returns.
Based on Viking Therapeutics Inc (VKTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -58.23. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 106.58.
Currently, EBITDA for the company is -100.53 million with net debt to EBITDA at 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.19.
Conclusion
To wrap up, the performance of Viking Therapeutics Inc (VKTX) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
